Omeros Corporation (NASDAQ:OMER) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Omeros Corporation (NASDAQ:OMER) have been given a consensus rating of “Moderate Buy” by the five analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $40.3333.

OMER has been the topic of several research analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Wednesday, October 15th. WBB Securities reaffirmed a “strong-buy” rating and set a $45.00 target price on shares of Omeros in a report on Wednesday, October 15th. Wall Street Zen cut shares of Omeros from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. HC Wainwright boosted their price objective on Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Tuesday, January 27th.

Omeros Trading Down 2.2%

OMER opened at $11.69 on Tuesday. Omeros has a 1-year low of $2.95 and a 1-year high of $17.65. The company has a market cap of $828.82 million, a price-to-earnings ratio of -5.79 and a beta of 2.38. The company’s fifty day moving average price is $12.01 and its two-hundred day moving average price is $7.59.

Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.39. As a group, equities analysts forecast that Omeros will post -3.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CAO David J. Borges sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 12.90% of the stock is owned by corporate insiders.

Institutional Trading of Omeros

Several large investors have recently bought and sold shares of the company. B. Riley Wealth Advisors Inc. purchased a new position in shares of Omeros during the second quarter valued at approximately $32,000. Harbour Investments Inc. grew its stake in shares of Omeros by 46.1% in the second quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 4,251 shares during the period. Tower Research Capital LLC TRC raised its stake in Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 11,971 shares during the last quarter. Sei Investments Co. purchased a new stake in Omeros during the second quarter valued at $40,000. Finally, Russell Investments Group Ltd. increased its position in shares of Omeros by 113.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 5,677 shares during the last quarter. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.